CJC 1295+Ipamorelin Combo 10 mg

Buy CJC 1295 Ipamorelin Research and Mechanism

Buy cjc 1295 ipamorelin for laboratory research into dual-pathway growth hormone axis stimulation. The CJC-1295/Ipamorelin combination pairs a synthetic GHRH analog with a selective growth hormone secretagogue, targeting two distinct receptor pathways that regulate pituitary GH release. According to research published in the Journal of Clinical Endocrinology & Metabolism, CJC-1295 produced dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more after a single injection, with an estimated half-life of 5.8-8.1 days and IGF-I elevation sustained for up to 28 days after multiple doses.citeweb_search:12#4 This sustained GHRH amplification provides the background sensitivity that Ipamorelin then triggers through the ghrelin receptor.

Research on the combination mechanism, published in PSPeptides dosage research, demonstrates that CJC-1295 amplifies pituitary somatotroph sensitivity through the GHRH pathway while Ipamorelin triggers the actual GH-release pulse through the GHSR (ghrelin receptor) pathway.citeweb_search:12#5 The combination produces a synergistic research signal larger than either compound alone at equivalent total doses. Ipamorelin is considered one of the most selective GH secretagogues available, with minimal activity on cortisol or prolactin secretion.citeweb_search:12#6 It is critical to emphasise that cjc 1295 ipamorelin is not approved by the TGA for human use. It is sold strictly for in vitro and laboratory research use only.

CJC 1295 Ipamorelin vs Sermorelin Research Comparison

CJC 1295 Ipamorelin vs Sermorelin Mechanism

According to comparative clinical data, Sermorelin is a 29-amino-acid fragment of natural GHRH that produces a gentler, more physiologic GH pulse through a single pathway. CJC-1295/Ipamorelin is a dual peptide that hits both GHRH and ghrelin receptors simultaneously, producing larger and longer-lasting GH elevations.citeweb_search:12#2 HealingMaps research confirms that Sermorelin alone mimics the body’s natural GHRH signal, while the CJC-1295/Ipamorelin stack creates two amplified signals that substantially exceed single-pathway output.citeweb_search:12#8

For research applications, cjc 1295 ipamorelin vs sermorelin selection depends on experimental design. Sermorelin is preferred for single-pathway GHRH receptor studies, gentle physiologic pulse modelling, and first-line GH axis research. CJC-1295/Ipamorelin is preferred for dual-receptor synergy studies, amplified GH pulse research, and investigations into combined GHRH plus secretagogue signalling.citeweb_search:12#2web_search:12#8

CJC 1295 Ipamorelin vs Tesamorelin Research

Researchers frequently investigate cjc 1295 ipamorelin vs tesamorelin because both compounds stimulate GH release but through different pathway architectures. According to comparative research data, Tesamorelin is a GHRH analogue studied primarily through the GHRH receptor pathway without an added secretagogue component. CJC-1295/Ipamorelin is a dual-pathway model involving GHRH receptor signalling plus GHSR-1a (ghrelin receptor) secretagogue activity.citeweb_search:13#2 Clinical comparison data shows that Tesamorelin has a more developed research record in visceral adiposity and metabolic endpoints, while CJC-1295/Ipamorelin offers broader GH optimisation across sleep, recovery, and multi-system signalling.citeweb_search:13#0 For laboratory research, Tesamorelin is positioned for targeted GHRH-specific metabolic studies; CJC-1295/Ipamorelin is positioned for dual-pathway endocrine signalling and GH pulse modelling.

CJC 1295 Ipamorelin vs MK-677 Research

The cjc 1295 ipamorelin vs MK-677 comparison highlights two different approaches to GH axis research. According to comparative research data, MK-677 is an orally bioavailable ghrelin mimetic with a long half-life of approximately 24 hours, producing sustained GH elevation rather than pulsatile release. CJC-1295/Ipamorelin creates sharp GH pulses that mimic natural endogenous rhythms, with CJC-1295 amplifying pituitary sensitivity and Ipamorelin providing clean, selective pulse triggers without cortisol or prolactin elevation.citeweb_search:13#3 MK-677 significantly increases appetite and has more pronounced metabolic effects on glucose and insulin; CJC-1295/Ipamorelin is preferred for research requiring pulsatile pattern preservation and cleaner metabolic profiles.citeweb_search:13#3

CJC 1295 Ipamorelin vs HGH Research

According to research published by Meto, growth hormone peptides differ fundamentally from synthetic HGH replacement. CJC-1295/Ipamorelin stimulates the pituitary to produce and release GH in a pattern that more closely resembles the body’s natural rhythm, rather than replacing the hormone entirely.citeweb_search:13#1 This distinction is biologically significant: exogenous HGH bypasses the pituitary and provides a constant circulating level, while CJC-1295/Ipamorelin preserves natural feedback loops and pulsatile secretion patterns. For laboratory research, HGH is positioned for direct hormone replacement studies; CJC-1295/Ipamorelin is positioned for endogenous axis stimulation, receptor synergy, and physiologic pulse modelling.

CJC 1295 Ipamorelin Dosage and Reconstitution

CJC 1295 Ipamorelin Dose for Research Protocols

For laboratory research, the cjc 1295 ipamorelin combo is typically supplied as a 10mg lyophilised blend. According to research protocol references, typical laboratory dosing involves 300mcg of each component per administration, 1 to 3 times daily depending on experimental design.citeweb_search:12#0 Clinical protocol data describes graduated escalation from 0.6mg daily in week one to 2.0mg maintenance by month three, with 5-days-on, 2-days-off weekly scheduling.citeweb_search:12#3 For in vitro applications, working concentrations should be calibrated to specific assay requirements. All dosing parameters are for laboratory research use only.

Reconstitution Guide

Remove the vial from freezer storage and allow it to equilibrate to room temperature for 15 to 20 minutes. Draw 2.0 mL of bacteriostatic water into a sterile syringe and inject slowly down the inner vial wall to minimise foaming. Gently swirl until fully dissolved. Do not shake vigorously. At 2.0 mL reconstitution, a 10mg vial yields 5mg/mL. Label with the reconstitution date and store at 2 to 8 degrees C protected from light. Use within 14 to 21 days. Do not freeze reconstituted solution.

How CJC 1295 Ipamorelin Compares to Other Research Compounds

CJC 1295 Ipamorelin vs Sermorelin

Sermorelin is a 29-amino-acid GHRH fragment that produces gentle, physiologic GH pulses through a single receptor pathway. CJC 1295 Ipamorelin is a dual-pathway combination that amplifies GHRH signalling while adding ghrelin receptor activation for larger, synergistic GH pulses. Sermorelin is preferred for single-pathway, natural-pattern GH research. CJC 1295 Ipamorelin is preferred for dual-receptor synergy, amplified pulse magnitude, and combined secretagogue studies. The choice depends on whether the research question requires single or dual-pathway stimulation.

CJC 1295 Ipamorelin vs Tesamorelin

Tesamorelin is a GHRH analogue studied for targeted visceral adiposity and metabolic endpoints through single-pathway GHRH receptor signalling. CJC 1295 Ipamorelin is a dual-pathway blend studied for broader GH axis optimisation, sleep architecture, and multi-system recovery. Tesamorelin is preferred for metabolic and body-composition research. CJC 1295 Ipamorelin is preferred for endocrine-axis signalling and pulsatile GH modelling. They are not interchangeable research tools.

CJC 1295 Ipamorelin vs MK-677

MK-677 is an orally bioavailable ghrelin mimetic with a 24-hour half-life that produces sustained GH elevation. CJC 1295 Ipamorelin is an injectable dual-pathway combination that produces sharp, pulsatile GH spikes mimicking natural physiology. MK-677 is preferred for oral administration and sustained GH elevation research. CJC 1295 Ipamorelin is preferred for pulsatile pattern research, receptor synergy studies, and cleaner metabolic profiles. They represent different administration routes and GH release kinetics.

CJC 1295 Ipamorelin vs HGH

HGH is exogenous human growth hormone that bypasses the pituitary and provides constant circulating levels. CJC 1295 Ipamorelin stimulates endogenous GH release through natural receptor pathways while preserving feedback loops and pulsatility. HGH is for direct hormone replacement research. CJC 1295 Ipamorelin is for endogenous axis stimulation and physiologic pulse modelling. They operate at fundamentally different levels of the GH-IGF-1 axis.

CJC 1295 Ipamorelin vs CJC-1295 No Dac Alone

CJC-1295 No DAC alone amplifies pituitary somatotroph sensitivity through the GHRH pathway but does not strongly trigger the GH-release pulse itself. CJC 1295 Ipamorelin adds Ipamorelin’s ghrelin receptor activation to trigger clean, selective GH pulses against the amplified background. CJC-1295 No DAC alone produces a smaller research signal. CJC 1295 Ipamorelin produces synergistic, larger pulses through dual-receptor convergence. They are related but not equivalent research models.

CJC 1295 Ipamorelin vs Ipamorelin Alone

Ipamorelin alone triggers GH-release pulses through the ghrelin receptor but without the sustained GHRH sensitivity amplification provided by CJC-1295. CJC 1295 Ipamorelin combines the sustained GHRH background signal with the acute secretagogue trigger, producing a substantially larger GH pulse than Ipamorelin alone at equivalent doses. Ipamorelin is for secretagogue-only research. CJC 1295 Ipamorelin is for combined pathway synergy research.

CJC 1295 Ipamorelin vs BPC-157

BPC-157 is a synthetic pentadecapeptide studied for tissue regeneration, wound healing, and angiogenesis through growth factor pathways. CJC 1295 Ipamorelin is a dual-pathway GH blend studied for endocrine axis stimulation and pulsatile GH release. BPC-157 is for structural repair research. CJC 1295 Ipamorelin is for hormonal and metabolic signalling research. They are entirely different research categories.

Product Specifications

Purity and Analysis

• Content: 10mg lyophilised powder (combo blend)
• Components: CJC-1295 (No DAC) + Ipamorelin
• CJC-1295 Sequence: Modified GRF (1-29) tetrasubstituted analog
• Ipamorelin Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
• Purity: Greater than or equal to 98% by HPLC
• Appearance: White to off-white lyophilised powder
• Source: Synthetic, manufactured via solid-phase peptide synthesis

Each batch is independently tested. Request the Certificate of Analysis (COA) for your specific batch number to verify purity, mass spec, and chromatography data.

Storage and Handling

• Lyophilised storage: -20 degrees C, protected from light and moisture
• Shelf life (unreconstituted): 24 months when stored correctly
• Handling: Use sterile technique. Avoid repeated freeze-thaw cycles

Shipping and Returns

We ship cjc 1295 ipamorelin from our Australian facility via express domestic courier. Orders placed before 2:00 PM AEST dispatch the same business day. All peptide orders are packaged in insulated, discreet packaging with cold-chain protection where required.

• Minimum order: $200 AUD
• Free shipping: Orders over $200 AUD
• Flat rate: $15 AUD for orders under $200
• Delivery time: 1 to 5 business days Australia-wide
• Returns: Unopened vials may be returned within 30 days of delivery for store credit or replacement. We do not accept returns on reconstituted or opened products due to stability concerns. Read the full returns policy.

Frequently Asked Questions

Buy cjc 1295 ipamorelin for research
Pure Peptide Factory supplies cjc 1295 ipamorelin as a research-grade dual-pathway GH blend for laboratory applications. Each vial contains 10mg lyophilised combo powder with HPLC verification and a Certificate of Analysis. Minimum order $200 AUD.

CJC 1295 ipamorelin vs sermorelin research
Sermorelin is a single GHRH pathway peptide producing gentle, natural-pattern GH pulses. CJC-1295/Ipamorelin is a dual-pathway combination producing larger, synergistic GH elevation through simultaneous GHRH and ghrelin receptor activation. Sermorelin is for single-pathway research; the combo is for dual-receptor synergy research.

CJC 1295 ipamorelin dosage for research
Research protocols typically reference 300mcg of each component per administration, 1 to 3 times daily, or graduated escalation from 0.6mg to 2.0mg daily over a multi-week cycle. Reconstitute a 10mg vial with 2.0 mL bacteriostatic water to yield 5mg/mL. All dosing is for laboratory research only.

CJC 1295 ipamorelin vs tesamorelin which is better
Neither is universally better. Tesamorelin is preferred for targeted GHRH-specific metabolic and visceral adiposity research. CJC-1295/Ipamorelin is preferred for dual-pathway GH pulse modelling, sleep architecture, and broad endocrine signalling research.

CJC 1295 ipamorelin vs MK-677 mechanism
MK-677 is an oral ghrelin mimetic with 24-hour half-life producing sustained GH elevation. CJC-1295/Ipamorelin is an injectable dual-pathway combination producing sharp, pulsatile GH spikes. MK-677 is for sustained elevation and oral delivery research; the combo is for pulsatile pattern and receptor synergy research.

Is cjc 1295 ipamorelin approved for human use
No. Cjc 1295 ipamorelin is strictly for research and laboratory use. It is not approved by the TGA for human consumption, therapeutic application, or clinical use. It is also banned by WADA.

Do you ship outside Australia
Currently, we only ship to Australian addresses. We do not export peptides due to varying international customs regulations.

How do I verify the purity of my batch
Every batch ships with a unique batch number. Enter this number on our COA lookup page to download the HPLC and mass spec report for your specific vial.